Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2024 Aug 1;144(5):471-472.
doi: 10.1182/blood.2024025047.

First, do no harm: quality over quantity?

Sara M Tinsley-Vance  1 , Jeffrey E Lancet  1
Affiliations
Editorial

First, do no harm: quality over quantity?

Sara M Tinsley-Vance et al. Blood. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

None
HRQoL and survival data were compared between 10-day decitabine 20 mg/m2 and daunorubicin 60 mg/m2 for 3 days and 7 days of cytarabine 100 mg/m2 (3 + 7). Similar survival and allo-HSCT rates between treatment groups are depicted on the left. The risk of HRQoL deterioration was lower in the decitabine group than in the 3 + 7 treatment group (on the right) at 2 months.
See this image and copyright information in PMC

Comment on

References

    1. Efficace F, Kicinski M, Coens C, et al. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. Blood. 2024;144(5):541–551. - PubMed
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organisation for Research and Treatment of Cancer QLQC30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365–376. - PubMed
    1. Wheelwright S, Darlington AS, Fitzsimmons D, et al. International validation of the EORTC QLQ-ELD14 questionnaire for assessment of health-related quality of life elderly patients with cancer. Br J Cancer. 2013;109(4):852–858. - PMC - PubMed
    1. Han K, Ren M, Wick W, et al. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials. Neuro Oncol. 2014;16(5):696–706. - PMC - PubMed
    1. Soto-Perez-de-Celis E, Li D, Sun C-L, et al. Patient-defined goals and preferences among older adults with cancer starting chemotherapy. Proc Am Soc Clin Oncol. 2018;36(15_suppl) (abstr)